Steven Lichtman
Stock Analyst at Oppenheimer
(4.21)
# 386
Out of 4,784 analysts
65
Total ratings
50%
Success rate
17.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steven Lichtman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DXCM DexCom | Maintains: Outperform | $115 → $105 | $69.47 | +51.14% | 8 | Oct 25, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $145 → $135 | $112.15 | +20.37% | 7 | Oct 15, 2024 | |
| MNKD MannKind | Maintains: Outperform | $10 → $12 | $5.10 | +135.29% | 2 | Aug 28, 2024 | |
| ALC Alcon | Maintains: Outperform | $103 → $110 | $96.80 | +13.64% | 3 | Aug 22, 2024 | |
| MDT Medtronic | Maintains: Perform | $92 → $94 | $88.98 | +5.64% | 10 | Aug 21, 2024 | |
| RXST RxSight | Maintains: Outperform | $72 → $65 | $26.67 | +143.72% | 8 | Aug 6, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Outperform | $47 → $58 | $19.81 | +192.78% | 1 | Jun 10, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $10 → $11 | $9.61 | +14.46% | 5 | May 9, 2024 | |
| ANGO AngioDynamics | Upgrades: Outperform | $12 | $9.83 | +22.08% | 2 | Apr 5, 2024 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $82 → $87 | $103.27 | -15.75% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $58 → $68 | $100.80 | -32.54% | 2 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $3.5 | $1.14 | +207.02% | 2 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $300 → $275 | $260.27 | +5.66% | 5 | Jan 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $273 → $288 | $367.54 | -21.64% | 2 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $105 | $103.57 | +1.38% | 3 | Jul 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | $150 | $17.57 | +753.73% | 1 | Jul 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $83 → $85 | $84.98 | +0.02% | 3 | Sep 4, 2020 |
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $69.47
Upside: +51.14%
Zimmer Biomet Holdings
Oct 15, 2024
Maintains: Outperform
Price Target: $145 → $135
Current: $112.15
Upside: +20.37%
MannKind
Aug 28, 2024
Maintains: Outperform
Price Target: $10 → $12
Current: $5.10
Upside: +135.29%
Alcon
Aug 22, 2024
Maintains: Outperform
Price Target: $103 → $110
Current: $96.80
Upside: +13.64%
Medtronic
Aug 21, 2024
Maintains: Perform
Price Target: $92 → $94
Current: $88.98
Upside: +5.64%
RxSight
Aug 6, 2024
Maintains: Outperform
Price Target: $72 → $65
Current: $26.67
Upside: +143.72%
Tandem Diabetes Care
Jun 10, 2024
Maintains: Outperform
Price Target: $47 → $58
Current: $19.81
Upside: +192.78%
BrainsWay
May 9, 2024
Maintains: Outperform
Price Target: $10 → $11
Current: $9.61
Upside: +14.46%
AngioDynamics
Apr 5, 2024
Upgrades: Outperform
Price Target: $12
Current: $9.83
Upside: +22.08%
Merit Medical Systems
Feb 29, 2024
Maintains: Outperform
Price Target: $82 → $87
Current: $103.27
Upside: -15.75%
Feb 1, 2024
Maintains: Perform
Price Target: $58 → $68
Current: $100.80
Upside: -32.54%
Sep 19, 2023
Reiterates: Outperform
Price Target: $3.5
Current: $1.14
Upside: +207.02%
Jan 31, 2022
Upgrades: Outperform
Price Target: $300 → $275
Current: $260.27
Upside: +5.66%
Jul 28, 2021
Maintains: Perform
Price Target: $273 → $288
Current: $367.54
Upside: -21.64%
Jul 14, 2021
Downgrades: Perform
Price Target: $105
Current: $103.57
Upside: +1.38%
Jul 9, 2021
Initiates: Perform
Price Target: $150
Current: $17.57
Upside: +753.73%
Sep 4, 2020
Maintains: Perform
Price Target: $83 → $85
Current: $84.98
Upside: +0.02%